ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half Of 2022
18 Août 2022 - 05:45PM
Business Wire
- Continued focus of the Services activity on the Biotech's
preclinical studies in ophthalmology
- Determination of the strategic axes of clinical development
in ophthalmology is ongoing
- Cash of €4.0 million (excluding Research Tax Credit) as of
June 30, 2022
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
today published its cash position for the 1st semester ended June
30, 2022 and reviewed the highlights of the period.
The company recorded a consolidated half-yearly turnover of
€2,630K, after elimination of intra-group transactions. IRIS Pharma
recorded half-year revenues of €3,028K. Concerning the activity
dedicated to the discovery and development of innovative therapies
aimed at improving the lives of patients, ABIONYX Pharma did not
generate any revenues during this half-year.
The consolidated turnover reflects the fact that since the
integration of IRIS Pharma, the biotech has decided to focus its
efforts on preclinical studies of bio-HDL in ophthalmology, in
order to determine the strategic development axes to enter the
clinical phase as soon as possible. As previously announced, the
company will shortly communicate its strategy in ophthalmology.
In the renal franchise, the Phase 2a clinical trial for CER-001,
called RACERS, is expected to be completed shortly in sepsis at
high risk of developing acute kidney injury, in partnership with
the University of Bari. In April, ABIONYX Pharma announced positive
interim results from this clinical trial that demonstrated a rapid
reversal of the cytokine cascade in sepsis patients, and a rapid
improvement in biomarkers of inflammation, including leukocytosis,
compared to standard therapy. Final study results will be available
in the fall of 2022.
In addition, the Company continues to receive new Compassionate
Access Authorization (CAA) requests for bio-HDL (CER-001) from
several hospitals around the world.
As of June 30, 2022, ABIONYX Pharma's cash position stood at
€4.0 million before receipt of the Research Tax Credit of ABIONYX
Pharma and IRIS Pharma. The company reminds that phase 2a is fully
financed and that no dilutive financial instrument has been put in
place.
Next financial release: 2022
Half-year results, September 29, 2022
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220818005466/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024